News / Blog
May Holidays 2023 - Pay Attention!
Zefix tablets 100 mg for chronic hepatitis B (lamivudine, Epivir)
Product Code :
Availability : 10
General information on Japanese Zefix tablets 100 mg for chronic hepatitis B (lamivudine, Epivir)
Package details: 70 tablets
Manufacturer: GlaxoSmithKline K.K., Japan
Active ingredients: lamivudine (chemical formula C8H11N3O3S)
Medical effect: Zefix tablets are effective for the treatment of chronic hepatitis B virus infection.
Contraindications and precautions: do not use for pregnant or breastfeeding women.
A patient should receive medical examination on a regular basis.
Store away from direct sunlight, heat and moisture.
If an allergic reaction occurs, stop using the medicine and consult with your doctor. If you’re taking any other medication or receiving any other treatment, you have to consult with your doctor before use.
Dosage and administration
For adults: take 1tablet (100 mg of lamivudine) once a day.
How effective are Zefix tablets 100 mg from Japan for chronic hepatitis B (lamivudine, Epivir)?
Zefix tablets contain lamivudine, a nucleoside reverse transcriptase inhibitor. It works by blocking reverse transcriptase, an enzyme essential for hepatitis B virus to reproduce in the body. Thus, Zefix tablets suppress the virus growth, decrease the amount of the virus in the blood and decrease the damage to the liver.
Who should use Zefix tablets 100 mg from Japan?
Zefix tablets are effective for the treatment of chronic hepatitis B virus infection. This medicine possesses the following features:
- helps to improve the histology staging of the liver,
- promotes normalization of seroconversion of e-antigen positive hepatitis B,
- can be used together with other antiretrovirals such as zidovudine and abacavir,
- shows no evidence of carcinogenicity or mutagenicity.
Studies also proved that lamivudine is generally safe and well-tolerated even for long-term treatment (C. L. Lai, R. N. Chien et al. “A one-year trial of lamivudine for chronic hepatitis B”. The New England journal of medicine, 1998, 339(2): 61-8).